Pacira Posts Topline Data From Knee Surgery Study With Its Flagship Pain Management Drug - Pacira BioScie

Pacira BioSciences Inc (NASDAQ:PCRX) announced topline results from its Phase 3 study of EXPAREL as a single-dose femoral nerve block in the adductor canal for postsurgical regional analgesia in patients undergoing total knee arthroplasty.
EXPAREL achieved the study's primary endpoint demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl.
EXPAREL also achieved a statistically significant reduction in postsurgical opioid consumption through 96 hours compared with bupivacaine HCl.
EXPAREL was well tolerated with a safety profile consistent with bupivacaine HCl.
Pacira plans to submit a supplemental marketing application to the FDA early next year seeking expansion of the EXPAREL label to include femoral nerve block in the adductor canal.
The company plans to submit the full results from the Phase 3 study for presentation at future scientific conferences and publication in a peer-reviewed journal.
Price Action: PCRX shares are up 0.35% at $51.42 on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.